BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38606616)

  • 1. Enhanced prostatic Esr1
    Sharkey C; Long X; Al-Faouri R; Strand D; Olumi AF; Wang Z
    J Pathol; 2024 Jul; 263(3):300-314. PubMed ID: 38606616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
    Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
    Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.
    Wang Z; Hu L; Salari K; Bechis SK; Ge R; Wu S; Rassoulian C; Pham J; Wu CL; Tabatabaei S; Strand DW; Olumi AF
    J Pathol; 2017 Dec; 243(4):457-467. PubMed ID: 28940538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
    Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
    Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
    Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
    J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
    Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
    Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
    J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.
    Ge R; Wang Z; Bechis SK; Otsetov AG; Hua S; Wu S; Wu CL; Tabatabaei S; Olumi AF
    Am J Pathol; 2015 Mar; 185(3):870-82. PubMed ID: 25700986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 12. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.
    Youn DH; Park J; Kim HL; Jung Y; Kang J; Jeong MY; Sethi G; Seok Ahn K; Um JY
    Oncotarget; 2017 Feb; 8(6):9500-9512. PubMed ID: 27880726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
    Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
    Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracts of
    Song KH; Seo CS; Yang WK; Gu HO; Kim KJ; Kim SH
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33803357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia.
    Liu Z; Lin Z; Cao F; Jiang M; Jin S; Cui Y; Niu YN
    BMC Urol; 2022 Nov; 22(1):172. PubMed ID: 36344974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland.
    Xue B; Wu S; Sharkey C; Tabatabaei S; Wu CL; Tao Z; Cheng Z; Strand D; Olumi AF; Wang Z
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):465-474. PubMed ID: 32029929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
    Nicholson TM; Ricke WA
    Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Ligustri Lucidi Fructus with Ecliptae Herba and their phytoestrogen or phytoandrogen like active pharmaceutical ingredients alleviate oestrogen/testosterone-induced benign prostatic hyperplasia through regulating steroid 5-α-reductase.
    Tao R; Liu E; Zhao X; Han L; Yu B; Mao H; Yang W; Gao X
    Phytomedicine; 2022 Jul; 102():154169. PubMed ID: 35636178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
    Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
    Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
    Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.